GLP-1 and Longevity

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It tells the brain you're full, slows how fast your stomach empties, and helps control insulin.

GLP-1 agonists are lab-made versions that copy that signal and stick around in the body much longer. The main drugs:

• Semaglutide, sold as Ozempic (diabetes) or Wegovy (obesity). Weekly injection.
• Tirzepatide, sold in the EU as Mounjaro for both type 2 diabetes and obesity (in the US, the obesity brand is Zepbound; Zepbound is not marketed in the EU). Hits two hunger receptors (GLP-1 and GIP) instead of one.
• Liraglutide, the older version. Daily injection.

These drugs were built for type 2 diabetes. But the weight loss in trials was so big (10 to 22 percent of body weight in phase-3 studies) that regulators also cleared them for obesity. The longevity question is separate: do they help people live longer or healthier, beyond just the weight loss?

This guide is not medical advice. GLP-1 agonists are prescription drugs with real risks. Talk to your doctor.

Here's the most important idea to get right: losing weight and living longer are not the same thing, even when they look related.

Long-running observational studies show obesity (BMI over 30) is linked to losing several years of life expectancy. So reversing obesity should in theory win some of those years back. But:

• Intentional weight loss effects on mortality depend heavily on the method. Bariatric surgery (the SOS/Swedish Obese Subjects cohort, Sjöström NEJM 2007) showed roughly a 20 to 30 percent relative reduction in all-cause mortality over 10-plus years. Lifestyle-only weight loss (Look-AHEAD, stopped early for futility in 2012) did NOT reduce cardiovascular events in people with type 2 diabetes — which is itself informative about how much of the benefit comes from weight loss alone versus the intervention that drives it.
• In people with a normal BMI, there is no evidence yet that GLP-1 extends life. Every trial has been in people with obesity or diabetes.
• Weight loss also costs you lean body mass, usually about 25 to 40 percent of the weight you lose. Lean body mass (what DEXA reports) includes skeletal muscle plus water, glycogen, bone, and organ tissue, so the pure skeletal-muscle share is smaller — but skeletal-muscle loss on GLP-1s is real, and losing it risks worse mobility and metabolic health later unless you add strength training and enough protein.

So the real longevity question is: are there benefits beyond the weight loss itself? Early studies point to a few believable ways that could work. But the data are still young.

Three big randomised trials drive the current longevity debate:

SELECT (Lincoff et al., NEJM 2023): 17,604 people with obesity and existing heart disease, but no diabetes. They took semaglutide 2.4 mg weekly with a mean exposure of 34.2 months (mean follow-up ~40 months). Primary endpoint: a 20 percent drop in major heart-and-blood-vessel events (3P-MACE — death, heart attack, stroke; HR 0.80, 95 percent CI 0.72 to 0.90). Semaglutide also showed a nominal reduction in all-cause mortality (HR 0.81, 95 percent CI 0.71 to 0.93), but an upstream endpoint in SELECT's pre-specified hierarchical testing sequence did not cross its boundary, so the mortality result is considered hypothesis-generating rather than statistically confirmed. It is still the strongest evidence so far for a heart-protective, and possibly lifespan-related, effect.

STEP-HFpEF (2023): Semaglutide in people with heart failure (the kind where the heart pumps but stays stiff) and obesity. Symptoms and exercise capacity improved.

FLOW (2024): Semaglutide in people with type 2 diabetes and chronic kidney disease. A 24 percent drop in major kidney and heart-and-blood-vessel events.

Metabolic dysfunction-associated steatohepatitis (MASH): ESSENCE Part 1 results supported the FDA approval of Wegovy (semaglutide 2.4 mg) for noncirrhotic MASH with moderate-to-advanced fibrosis (F2-F3) on 15 August 2025. The EMA CHMP adopted a positive opinion at its 26–29 January 2026 meeting recommending conditional marketing authorisation under the EU brand name Kayshild; EC decision pending at time of writing. Tirzepatide is not approved for MASH in any jurisdiction as of May 2026, despite social-media claims to the contrary; Phase 2 SYNERGY-NASH (Loomba et al., NEJM 2024) is the published evidence to date.

What we still don't know:

• Direct lifespan data over 10-plus years
• The effect in people without risk factors (healthy-weight BMI)
• Long-term safety across multiple decades
• Whether the benefits stick around after you stop (early hint: most of the weight comes back within 1 to 2 years)

SELECT-LIFE, a non-interventional observational follow-up of SELECT participants, is ongoing and may provide longer-term outcomes data. It is not a randomised mortality arm, so hard lifespan answers will still need a dedicated trial.

GLP-1 agonists are not harmless supplements. Common and serious risks include:

Common (10 to 40 percent of users):

• Nausea, especially in the first weeks
• Diarrhoea or constipation
• Vomiting
• Loss of appetite (that's the point, but it can tip into eating too little)

Less common but serious:

• Pancreatitis (inflamed pancreas). Get medical help right away.
• Gallbladder problems, including a higher risk of gallstones and cholecystitis.
• Gastroparesis (stomach empties too slowly). The ASA's 2023 consensus recommended pausing weekly GLP-1 agonists for one week and daily agents on the day of the procedure before anaesthesia or deep sedation. The October 2024 multi-society update (ASA, AGA, ASMBS, ISPCO, SAGES) softened that universal rule into a risk-stratified, shared-decision approach (e.g., gastric ultrasound, dietary modification) rather than automatic discontinuation. Either way, tell your anaesthetist what you take — pulmonary aspiration from retained gastric contents has been reported.
• Acute kidney injury from dehydration if nausea or vomiting prevent adequate fluid intake.
• Medullary thyroid carcinoma (MTC) and MEN-2: warning per EMA SmPC §4.4 (not §4.3 contraindications) and FDA boxed warning. Personal or family history of MTC or Multiple Endocrine Neoplasia type 2 is treated as a hard stop in clinical practice. The label is based on rodent thyroid C-cell tumour findings; the human risk is uncertain but prescribing is generally avoided.
• Non-arteritic anterior ischaemic optic neuropathy (NAION): a visual-loss signal was first reported with semaglutide in Hathaway et al., JAMA Ophthalmology 2024 (HR 4.28, 95 percent CI 1.62 to 11.29, single-centre cohort); the larger OHDSI multi-database replication (Cai et al., JAMA Ophthalmology, April 2025, 14 databases, 37.1M T2D adults) reported a meta-analysis IRR of approximately 1.32 (95% CI 1.14 to 1.54) — characterised in the abstract as "a modest increase in the risk of NAION ... smaller than that previously reported." A separate Danish-Norwegian cohort (Hjelholt et al., 2025) reported a pooled HR of 2.81 (95% CI 1.67–4.75). Following the PRAC conclusion of 5 June 2025, the semaglutide SmPCs were updated through autumn 2025 to list NAION as a very rare (<1/10,000) adverse reaction. Seek urgent ophthalmology review for sudden painless vision loss.
• Diabetic retinopathy worsening in patients with pre-existing retinopathy (SUSTAIN-6 signal).
• Muscle and bone loss if you don't plan around it.

Mental health: Reports of mood changes and, in a few cases, suicidal thoughts are still being reviewed by regulators. The EMA PRAC concluded in April 2024 that no cause-and-effect link was proven, but monitoring continues.

Cost and supply (Germany): Wegovy and Mounjaro for obesity are excluded from GKV reimbursement under §34 Abs. 1 Satz 7 SGB V (Lifestyle-Arzneimittel, AM-RL Anlage II) — always self-pay in Germany, roughly €170–500 per month depending on drug and dose (Wegovy maintenance dose ~€277/month after Novo Nordisk's price cut in April 2025; Mounjaro €206–489/month after Lilly's price increase in February 2025). Ozempic (semaglutide, up to 2 mg) and Mounjaro for type-2 diabetes are reimbursed on the approved indication via your diabetologist or internist; off-label prescribing of Ozempic for obesity without diabetes violates GKV rules and has drawn repeated KBV correspondence. BfArM issued warnings in 2023–2024 about counterfeit Ozempic circulating during shortage-driven grey-market imports — only fill prescriptions at licensed pharmacies.

For the longevity community, the picture has nuance.

If you have obesity or type 2 diabetes: the data are now solid enough that GLP-1 agonists count among the most effective tools we have, with direct heart and kidney benefits. That decision belongs with a doctor, ideally one with endocrinology or cardiology expertise.

At a normal weight, optimising for longevity: this is speculation, not science. Off-label low-dose use gets talked about in longevity circles (especially in the US), but the evidence is basically not there. The known risks (muscle loss, gut side effects, rare serious problems) don't disappear just because the proven benefit isn't there yet.

Non-negotiable companions to any GLP-1 use:

• Strength training (2 to 3 times a week) to keep muscle
• Higher protein intake (1.6 to 2.0 g per kg body weight)
• Regular DEXA or InBody scans to track body composition
• Heart checkups and blood work per your doctor's plan

Qualification ladder for German readers:

• BMI ≥30 alone (obesity), OR BMI 27 to <30 with at least one weight-related comorbidity (dysglycaemia/prediabetes/T2DM, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease) → Wegovy is indicated per the EMA SmPC. BMI ≥30 does not require a comorbidity. Statutory insurance (GKV) will not reimburse for obesity (AM-RL Anlage II Lifestyle-Arzneimittel exclusion), but a private Rezept via your Hausarzt or an Adipositas-Schwerpunktpraxis is legal and standard. Self-pay roughly €170-500 per month depending on drug and dose.
• Type 2 diabetes (any BMI) → Ozempic or Mounjaro are reimbursed by GKV on indication, via your diabetologist or internist.
• Normal BMI, seeking "longevity" → no clinical indication. Off-label prescribing for this purpose is very rare in Germany and not supported by existing trials.

Monitoring checklist:

• Baseline (before first injection): HbA1c, TSH, fasting glucose, lipid panel, lipase, eGFR, liver enzymes. Pregnancy test where relevant. Document starting weight and body composition (DEXA or InBody) if possible.
• Weeks 0-16 (titration): nausea is normal early; slow the dose escalation if vomiting persists for ≥1 week. Track weight weekly.
• Quarterly ongoing: HbA1c, lipid panel, lipase, renal function. DEXA or InBody every 6 months to catch lean-mass loss.
• Stop signals: persistent vomiting or dehydration, lipase rising above 3× the upper limit of normal, gallbladder pain, unexplained neck swelling, pregnancy.

Muscle-protection protocol: Minimum while on GLP-1: 3 full-body strength sessions per week at RPE 7-8, 2-3 reps in reserve. Protein 1.6-2.0 g per kg body weight. DEXA at baseline and 6 months. If lean-mass loss exceeds 10% over 6 months, slow the dose or pause.

Women's-health note: For menstruating women, GLP-1s can change cycle length and interact with oral contraceptives — delayed gastric emptying reduces absorption. Discuss contraception with your gynaecologist; back-up barrier methods are recommended during titration and for 4 weeks after each dose increase. There are no human pregnancy safety data; stop at least 2 months before planned conception.

What the research actually says: a healthy body is the means, not the goal. Any tool that reverses obesity has plausible longevity potential. But thinness at any cost is not a health goal. GLP-1 with training is not the same outcome as GLP-1 without training.